| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,¶,¶
,
* Veterans Affairs Medical Center, Memphis, TN 38104; Departments of
Medicine and
Pathology, University of Tennessee Health Science Center, Memphis, TN 38163;
Neuroimmunology Research, Veterans Affairs Medical Center, Portland, OR 00000; and
¶ Department of Neurology, Oregon Health and Science University, Portland, OR 97201
A number of clinical and experimental observations have been made relating elevated estrogen levels with the amelioration of autoimmune diseases, yet questions remain about the levels required for efficacy as well as the mechanism of disease inhibition. Using the collagen-induced arthritis (CIA) model, we have studied the effects of physiological, sustained levels of 17
-estradiol in preventing the development of autoimmune arthritis and analyzed the changes in the autoimmune response. Using time-release pellets of 17-estradiol, arthritis development was significantly inhibited in three different strains of CIA-susceptible mice compared with the effect of placebo treatment, and serum estradiol levels similar to those of mice in estrus were found to be equally effective as higher estradiol concentrations. Analysis of the autoimmune response in the estradiol-treated mice indicated that T cell production of IFN-
was markedly decreased, and significant decreases were also observed in levels of IL-10 and GM-CSF produced by lymph nodes cells from estradiol-treated mice. Although the total IgG anti-CII response was only minimally affected by estrogen treatment, a significant reduction in the levels of IgG2a anti-CII Abs and an increase in the levels of IgG1 anti-CII Abs were observed in estradiol-treated mice. These data indicate that estradiol treatment altered the Th profile of the autoimmune T cell response, which, in turn, altered the production of IgG Abs to an isotype that is poor at fixing complement, an important component in the immunopathogenesis of CIA.
This article has been cited by other articles:
|
|
 |
|
  R. H. Straub The Complex Role of Estrogens in Inflammation Endocr. Rev., August 1, 2007; 28(5): 521 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Santora, C. Rasa, D. Visco, B. G. Steinetz, and C. A. Bagnell Antiarthritic Effects of Relaxin, in Combination with Estrogen, in Rat Adjuvant-Induced Arthritis J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 887 - 893. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Dai, R. A. Phillips, and S. A. Ahmed Despite Inhibition of Nuclear Localization of NF-{kappa}B p65, c-Rel, and RelB, 17-beta Estradiol Up-Regulates NF-{kappa}B Signaling in Mouse Splenocytes: The Potential Role of Bcl-3 J. Immunol., August 1, 2007; 179(3): 1776 - 1783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K H Costenbader and E W Karlson Cigarette smoking and autoimmune disease: what can we learn from epidemiology? Lupus, November 1, 2006; 15(11): 737 - 745. [Abstract] [PDF]
|
|
|
|
|
|
L. Delpy, V. Douin-Echinard, L. Garidou, C. Bruand, A. Saoudi, and J.-C. Guery Estrogen Enhances Susceptibility to Experimental Autoimmune Myasthenia Gravis by Promoting Type 1-Polarized Immune Responses J. Immunol., October 15, 2005; 175(8): 5050 - 5057. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bouman, M. J. Heineman, and M. M. Faas Sex hormones and the immune response in humans Hum. Reprod. Update, July 1, 2005; 11(4): 411 - 423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Nancy and S. Berrih-Aknin Differential Estrogen Receptor Expression in Autoimmune Myasthenia Gravis Endocrinology, May 1, 2005; 146(5): 2345 - 2353. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
